The potential of serum amyloid A-LDL as a novel biomarker for cardiovascular disease risk

Clinical Lipidology

Volumn 5, Issue 4, 2010, Pages 489-495

  Kotani, Kazuhiko ^a,b,c   Satoh, Noriko ^b   Yamada, Toshiyuki ^a   Gugliucci, Alejandro ^c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^c TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

cardiovascular disease; hypercholesterolemia; hyperlipidemia; inflammation; metabolic syndrome; oxidation; oxidized LDL; serum amyloid A

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID A PROTEIN; ANTIOXIDANT; BETA CAROTENE; BEZAFIBRATE; BIOLOGICAL MARKER; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN MODIFICATION; REVIEW; RISK ASSESSMENT;

EID: 77955568506     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.42     Document Type: Review

References (50)

1. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88(6), 1785-1792 (1991).
2. Holvoet P: Oxidized LDL and coronary heart disease. Acta Cardiol. 59(5), 479-484 (2004).
3. Chen HW, Kuo CL, Huang CS, Kuo SJ, Liu CS: Oxidized low-density lipoproteins, autoantibodies against oxidized low-density lipoproteins and carotid intima media thickness in a clinically healthy population. Cardiology 110(4), 252-259 (2008).
4. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320(14), 915-924 (1989).
5. Witztum JL, Steinberg D: The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc. Med. 11(3-4), 93-102 (2001).
6. Steinberg D: The LDL modification hypothesis of atherogenesis: an update. J. Lipid Res. 50(Suppl.), S376-S381 (2009).
7. Itabe H, Ueda M: Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J. Atheroscler. Thromb. 14(1), 1-11(2007).
8. Mashiba S, Ogasawara K, Takeya M et al.: Development of blood examination method of serum amyloid A and LDL complex, and clinical application to prediction of cardiovascular event. Rinsho Byori 52(1), 67-74 (2004).
9. Malle E, de Beer FC: Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur. J. Clin. Invest. 26(6), 427-435 (1996).
10. Yamada T: Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin. Chem. Lab. Med. 37(4), 381-388 (1999).
11. Benditt EP, Eriksen N: Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc. Natl Acad. Sci. USA 74(9), 4025-4028 (1977).
12. Benditt EP, Eriksen N, Hanson RH: Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein. Proc. Natl Acad. Sci. USA 76(8), 4092-4096 (1979).
13. van der Westhuyzen DR, de Beer FC, Webb NR: HDL cholesterol transport during inflammation. Curr. Opin. Lipidol. 18(2), 147-151 (2007).
14. van Lenten BJ, Hama SY, de Beer FC et al.: Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96(6), 2758-2767 (1995).
15. Ogasawara K, Mashiba S, Wada Y et al.: A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. Atherosclerosis 174(2), 349-356 (2004).
16. Kotani K, Satoh N, Kato Y et al.; Japan Obesity and Metabolic Syndrome Study Group: A novel oxidized low-density lipoprotein marker, serum amyloid A-LDL, is associated with obesity and the metabolic syndrome. Atherosclerosis 204(2), 526-531 (2009).
17. Sigurdardottir V, Fagerberg B, Hulthe J: Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58 year-old men (AIR study). J. Intern. Med. 252(5), 440-447 (2002).
18. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr: Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 299(19), 2287-2293 (2008).
19. Holvoet P, De Keyzer D, Jacobs DR: Oxidized LDL and the metabolic syndrome. Future Lipidol. 3(6), 637-649 (2008).
20. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity: New criteria for 'obesity disease' in Japan. Circ. J. 66(11), 987-992 (2002).
21. Nakamura T, Tsubono Y, Kameda Takemura K et al.; Group of the Research for the Association between Host Origin and Atherosclerotic Diseases under the Preventive Measure for Work-related Diseases of the Japanese Labor Ministry: Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees: a case-control study. Jpn Circ. J. 65(1), 11-17 (2001).
22. Ridker PM, Glynn RJ, Hennekens CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97(20), 2007-2011 (1998).
23. Koenig W, Sund M, Fróhlich M et al.: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg cohort study, 1984 to 1992. Circulation 99(2), 237-242 (1999).
24. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W: Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 112(5), 651-657 (2005).
25. Kawano J, Arora R: The role of adiponectin in obesity, diabetes, and cardiovascular disease. J. Cardiometab. Syndr. 4(1), 44-49 (2009).
26. Sweeney G: Cardiovascular effects of leptin. Nat. Rev. Cardiol. 7(1), 22-29 (2010).
27. Kotani K, Koibuchi H, Yamada T, Taniguchi N: The effects of lifestyle modification on a new oxidized low-density lipoprotein marker, serum amyloid A-LDL, in subjects with primary lipid disorder. Clin. Chim. Acta 409(1-2), 67-69 (2009).
28. Yamamoto R, Kawamura T, Wakai K et al.: Favorable life-style modification and attenuation of cardiovascular risk factors. Jpn Circ. J. 63(3), 184-188 (1999).
29. Kotani K, Mu H, Kamezaki S, Kato T, Kurozawa Y: Clinical importance of the evaluation of blood non-HDL cholesterol levels in a hypercholesterolemia education class. Intern. Med. 45(10), 697-698 (2006).
30. Grundy SM: Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat. Rev. Drug Discov. 5(4), 295-309 (2006).
31. Rau O, Zettl H, Popescu L, Steinhilber D, Schubert-Zsilavecz M: The treatment of dyslipidemia-what's left in the pipeline? Chem. Med. Chem. 3(2), 206-221 (2008).
32. Knopp RH, Paramsothy P, Atkinson B, Dowdy A: Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. Am. J. Cardiol. 101(8A), B48-B57 (2008).
33. Bianchi C, Penno G, Romero F, Del Prato S, Miccoli R: Treating the metabolic syndrome. Expert Rev. Cardiovasc. Ther. 5(3), 491-506 (2007).
34. Magkos F, Yannakoulia M, Chan JL, Mantzoros CS: Management of the metabolic syndrome and Type 2 diabetes through lifestyle modification. Annu. Rev. Nutr. 29, 223-256 (2009).
35. [Japan Atherosclerosis Society guidelines for diagnosis and treatment of atherosclerotic cardiovascular diseases.] Japan Atherosclerosis Society, Japan, 24-26 (2002).
36. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ: Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197(1), 12-24 (2008).
37. Satoh N, Shimatsu A, Kotani K et al.: Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and CRP in metabolic syndrome. Diabetes Care 30(1), 144-146 (2007).
38. Yokoyama M, Origasa H, Matsuzaki M et al.; Japan EPA Lipid Intervention Study (JELIS) Investigators: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369(9567), 1090-1098 (2007).
39. Satoh N, Shimatsu A, Kotani K et al.: Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens. Res. 32(11), 1004-1008 (2009).
40. Shirai K, Utino J, Otsuka K, Takata M: A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J. Atheroscler. Thromb. 13(2), 101-107 (2006).
41. Satoh N, Shimatsu A, Kato Y et al.: Evaluation of cardio-ankle vascular index, a new indicator of arterial stiffness independent of blood pressure, in obesity and metabolic syndrome. Hypertens. Res. 31(10), 1921-1930 (2008).
42. Elkeles RS, Diamond JR, Poulter C et al.: Cardiovascular outcomes in Type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 21(4), 641-648 (1998).
43. Milionis HJ, Elisaf MS, Mikhailidis DP: Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Curr. Med. Res. Opin. 16(1), 21-32 (2000).
44. Remick J, Weintraub H, Setton R, Offenbacher J, Fisher E, Schwartzbard A: Fibrate therapy: an update. Cardiol. Rev. 16(3), 129-141 (2008).
45. Yamazaki K, Kuromitsu J, Tanaka I: Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator-activated receptor a agonists. Biochem. Biophys. Res. Commun. 290(3), 1114-1122 (2002).
46. Hoffman R, Brook GJ, Aviram M: Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 93(1-2), 105-113 (1992).
47. Zambrana JL, López-Miranda J, Blanco A et al.: Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia. J. Heart Lung Transplant. 17(12), 1213-1219 (1998).
48. de Man FH, Jonkers IJ, Schwedhelm E et al.: Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia: effects of bezafibrate therapy. Arterioscler. Thromb. Vasc. Biol. 20(11), 2434-2440 (2000).
49. Kotani K, Satoh N, Yamada T: Bezafibrate and serum amyloid A-low-density lipoprotein complex in patients with Type 2 diabetes mellitus and hypertriglyceridemia. Eur. J. Intern. Med. 21(2), E10 (2010).
50. Wiklund O, Mattsson-Hultén L, Hurt Camejo E, Oscarsson J: Effects of simvastatin and atorvastatin on inflammation markers in plasma. J. Intern. Med. 251(4), 338-347 (2002).